Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | EVP & CHRO | March 10, 2023 | March 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date March 10, 2023 · Filed March 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,446 |
Ending reported balance
After 2023-03-13 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2023-03-10 · Grant · Acquired 2,532 · Balance 21,137 Row 2 · 2023-03-11 · Tax withholding · Disposed 483 · Balance 20,654 Row 3 · 2023-03-11 · Tax withholding · Disposed 277 · Balance 20,377 Row 4 · 2023-03-12 · Tax withholding · Disposed 448 · Balance 19,929 Row 5 · 2023-03-12 · Tax withholding · Disposed 269 · Balance 19,660 Row 6 · 2023-03-12 · Tax withholding · Disposed 255 · Balance 19,405 Row 7 · 2023-03-13 · Tax withholding · Disposed 659 · Balance 18,746 Row 8 · 2023-03-13 · Tax withholding · Disposed 300 · Balance 18,446 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.87 · Expires 2031-03-10 | Direct | 6,201 |
Reported balance
After 2023-03-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-03-10 · Grant · Acquired 6,201 · Balance 6,201 F1: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/10/2023. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/10/2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Catalent, Inc.
Report date December 18, 2024 · Filed December 18, 2024
Section 16 reporting ended · disclosed 2024-12-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-12-18 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-12-18 · Disposition to issuer · Disposed 39,366 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: Includes restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration"). F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms. Row 2 · 2024-12-18 · Grant · Acquired 12,032 · Balance 12,032 F5: At the Effective Time, each performance stock unit ("PSU"), whether or not vested, outstanding immediately prior to the Effective Time vested based on the greater of (i) the target level of performance or (ii) the actual level of performance as of the Effective Time as determined by the Issuer's board of directors or a committee thereof in its reasonable discretion (other than all then-outstanding awards of PSUs for which the applicable performance period has been completed and the actual level of performance has been certified, in each case, prior to the Effective Time, which vested in accordance with the actual level of performance). PSUs granted with respect to the fiscal 2023-2025 performance period vested at the target level of performance and PSUs granted with respect to the fiscal 2024-2026 performance period vested at 150%, the actual level of performance as of the Effective Time. Row 3 · 2024-12-18 · Disposition to issuer · Disposed 12,032 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F6: At the Effective Time, each outstanding PSU was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the PSU as determined in accordance with the Merger Agreement multiplied by (ii) the Merger Consideration. |
| Options to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $46.51 · Expires 2033-08-01 | Direct | 0 |
Reported balance
After 2024-12-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-12-18 · Disposition to issuer · Disposed 14,225 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F7: At the Effective Time, each stock option, whether or not vested, outstanding immediately before the Effective Time vested (if unvested) and was cancelled and entitled the holder of such option to receive an amount in cash, without interest, equal to the product of (i) the excess, if any, of (A) the Merger Consideration over (B) the per-share exercise price for such option multiplied by (ii) the total number of shares of Issuer common stock underlying such option. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
F2: Includes restricted stock units ("RSUs").
F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration").
F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms.
F5: At the Effective Time, each performance stock unit ("PSU"), whether or not vested, outstanding immediately prior to the Effective Time vested based on the greater of (i) the target level of performance or (ii) the actual level of performance as of the Effective Time as determined by the Issuer's board of directors or a committee thereof in its reasonable discretion (other than all then-outstanding awards of PSUs for which the applicable performance period has been completed and the actual level of performance has been certified, in each case, prior to the Effective Time, which vested in accordance with the actual level of performance). PSUs granted with respect to the fiscal 2023-2025 performance period vested at the target level of performance and PSUs granted with respect to the fiscal 2024-2026 performance period vested at 150%, the actual level of performance as of the Effective Time.
F6: At the Effective Time, each outstanding PSU was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the PSU as determined in accordance with the Merger Agreement multiplied by (ii) the Merger Consideration.
F7: At the Effective Time, each stock option, whether or not vested, outstanding immediately before the Effective Time vested (if unvested) and was cancelled and entitled the holder of such option to receive an amount in cash, without interest, equal to the product of (i) the excess, if any, of (A) the Merger Consideration over (B) the per-share exercise price for such option multiplied by (ii) the total number of shares of Issuer common stock underlying such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2021 Filed Apr 15, 2021 20:11 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 1,785 | $43.68 | $77,968.80 |
DisclosureSEC source: 0001209191-21-026819 · doc4.xml · nonDerivative · entry 4 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:11 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 3,440 | $70.00 | $240,800.00 |
DisclosureSEC source: 0001209191-21-026819 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,825 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:11 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 3,440 | $56.23 | $193,431.20 |
DisclosureSEC source: 0001209191-21-026819 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 20:11 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 1,081 | $70.00 | $75,670.00 |
DisclosureSEC source: 0001209191-21-026819 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,825 F1 · kind: The transactions reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:11 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 111 | $68.10 | $7,559.10 |
DisclosureSEC source: 0001209191-21-020762 · doc4.xml · nonDerivative · entry 4 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,906 Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:11 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 188 | $68.10 | $12,802.80 |
DisclosureSEC source: 0001209191-21-020762 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,017 Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:11 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 112 | $68.10 | $7,627.20 |
DisclosureSEC source: 0001209191-21-020762 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,205 Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:11 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,472 | $0.00 Strike: $68.10 | $0.00 |
DisclosureSEC source: 0001209191-21-020762 · doc4.xml · derivative · entry 5 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,472 Underlying: Common Stock · 5,472 shares Expires 2029-03-12 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/12/2021. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:11 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020762 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,317 Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,552 | $0.00 Strike: $43.68 | $0.00 |
DisclosureSEC source: 0001209191-20-057612 · doc4.xml · derivative · entry 7 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,785 Underlying: Common Stock · 2,552 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares of stock options will vest each of the first, second, third and fourth anniversaries of the grant date of 03/13/2017. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,424 | $0.00 Strike: $32.59 | $0.00 |
DisclosureSEC source: 0001209191-20-057612 · doc4.xml · derivative · entry 6 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,424 shares Expires 2024-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares of stock options will vest each of the first, second, third and fourth anniversaries of the grant date of 03/14/2016. F2 · balance_after: This stock option was previously reported as covering 2,212 shares of common stock at an exercise price of $65.17 per share. In accordance with the terms of the stock option plan, the exercise price of the option and number of shares subject to the option have been adjusted to reflect the two-for-one stock split that occurred on December 21, 2016. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 2,552 | $55.18 | $140,824.46 |
DisclosureSEC source: 0001209191-20-057612 · doc4.xml · nonDerivative · entry 5 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,502 Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 2,552 | $43.68 | $111,471.36 |
DisclosureSEC source: 0001209191-20-057612 · doc4.xml · nonDerivative · entry 4 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 4,424 | $51.00 | $225,624.00 |
DisclosureSEC source: 0001209191-20-057612 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,502 Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Exercise / conversionCommon Stock | 4,424 | $32.59 | $144,156.04 |
DisclosureSEC source: 0001209191-20-057612 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:10 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 754 | $51.00 | $38,454.00 |
DisclosureSEC source: 0001209191-20-057612 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Executive Vice President &CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,502 Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 2,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-044668 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · EVP & Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,256 Read SEC document |
| August 01, 2020 Filed Aug 4, 2020 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 286 | $47.75 | $13,656.50 |
DisclosureSEC source: 0001209191-20-044668 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · EVP & Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,169 Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:18 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 3,475 | $55.00 | $191,125.00 |
DisclosureSEC source: 0001209191-20-034969 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,455 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,361 | $0.00 Strike: $43.39 | $0.00 |
DisclosureSEC source: 0001209191-20-019561 · doc4.xml · derivative · entry 8 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,361 Underlying: Common Stock · 10,361 shares Expires 2028-03-13 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/13/2020. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 393 | $43.39 | $17,052.27 |
DisclosureSEC source: 0001209191-20-019561 · doc4.xml · nonDerivative · entry 7 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,930 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 269 | $43.39 | $11,671.91 |
DisclosureSEC source: 0001209191-20-019561 · doc4.xml · nonDerivative · entry 6 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,323 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 260 | $43.39 | $11,281.40 |
DisclosureSEC source: 0001209191-20-019561 · doc4.xml · nonDerivative · entry 5 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,592 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-019561 · doc4.xml · nonDerivative · entry 4 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,852 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 108 | $43.39 | $4,686.12 |
DisclosureSEC source: 0001209191-20-019561 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,777 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 111 | $43.39 | $4,816.29 |
DisclosureSEC source: 0001209191-20-019561 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,885 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 20:14 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 105 | $43.39 | $4,555.95 |
DisclosureSEC source: 0001209191-20-019561 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,996 Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:39 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 981 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010179 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,101 F3 · shares: On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019 under the March 13, 2019 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2020 at 97% of target, the first anniversary of the grant date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:39 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010179 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,120 F2 · shares: On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019 under the March 13, 2018 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2020 at 97% of target, the second anniversary of the grant date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:39 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010179 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,173 F1 · shares: On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019, at least 9% and up to a maximum of 33% cumulative increase in annual revenue over the 2016 fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 34% of the shares will vest on March 13, 2020 at 150% of target, the third anniversary of the grant date. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 22:11 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044337 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,742 Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 20:31 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 2,380 | $63.00 | $149,940.00 |
DisclosureSEC source: 0001209191-19-043665 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,588 Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 22:54 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 1,291 | $55.90 | $72,166.90 |
DisclosureSEC source: 0001209191-19-020108 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,968 Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 21:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 89 | $56.14 | $4,996.46 |
DisclosureSEC source: 0001209191-19-019765 · doc4.xml · nonDerivative · entry 7 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,259 Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 21:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 331 | $56.14 | $18,582.34 |
DisclosureSEC source: 0001209191-19-019765 · doc4.xml · nonDerivative · entry 6 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,348 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,491 | $0.00 Strike: $55.91 | $0.00 |
DisclosureSEC source: 0001209191-19-019765 · doc4.xml · derivative · entry 8 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,491 Underlying: Common Stock · 5,491 shares Expires 2027-03-13 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/13/2019. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019765 · doc4.xml · nonDerivative · entry 5 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,679 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 108 | $55.91 | $6,038.28 |
DisclosureSEC source: 0001209191-19-019765 · doc4.xml · nonDerivative · entry 4 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,452 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 102 | $55.91 | $5,702.82 |
DisclosureSEC source: 0001209191-19-019765 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,560 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 240 | $55.91 | $13,418.40 |
DisclosureSEC source: 0001209191-19-019765 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,662 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:21 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 381 | $55.91 | $21,301.71 |
DisclosureSEC source: 0001209191-19-019765 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,902 Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 22:16 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 874 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011198 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,283 F3 · shares: On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018 under the March 13, 2018 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2019 at 89.5% of target, the first anniversary of the grant date. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 22:16 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommn Stock | 1,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011198 · doc4.xml · nonDerivative · entry 2 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,409 F2 · shares: On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 33% of the shares will vest on March 13, 2019 at 150% of target, the second anniversary of the grant date. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 22:16 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011198 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,020 F1 · shares: On February 14, 2019, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2018, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 34% of the shares will vest on March 14, 2019 at 150% of target, the third anniversary of the grant date. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:23 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingLisa Evoli | 271 | $47.41 | $12,848.11 |
DisclosureSEC source: 0001209191-19-007480 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,814 Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:37 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 4,432 | $63.10 | $279,664.96 |
DisclosureSEC source: 0001209191-18-046239 · doc4.xml · nonDerivative · entry 1 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,085 F1 · price: The price shown above represents the weighted average price of the shares sold. The range of the sale prices was $63.0901 to $63.1029. Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 20:23 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 321 | $56.14 | $18,020.94 |
DisclosureSEC source: 0001209191-18-019840 · doc4.xml · nonDerivative · entry 5 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,517 Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 20:23 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 86 | $56.14 | $4,828.04 |
DisclosureSEC source: 0001209191-18-019840 · doc4.xml · nonDerivative · entry 4 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,838 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:23 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,587 | $0.00 Strike: $56.23 | $0.00 |
DisclosureSEC source: 0001209191-18-019840 · doc4.xml · derivative · entry 6 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,587 Underlying: Common Stock · 4,587 shares Expires 2026-03-13 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/13/2018. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:23 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 381 | $56.23 | $21,423.63 |
DisclosureSEC source: 0001209191-18-019840 · doc4.xml · nonDerivative · entry 3 Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,924 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.